MODERN APPROACHES TO THE TREATMENT OF ARTHROPATHIC PSORIASIS
DOI:
https://doi.org/10.5281/zenodo.16353819Abstract
Arthropathic psoriasis (psoriatic arthritis) is a severe chronic condition that occurs in approximately 20–30% of patients with psoriasis. Without timely diagnosis and adequate therapy, it can lead to persistent joint deformities, impaired work capacity, and disability. In recent years, significant progress has been made in understanding the pathogenesis of the disease, which has led to the development of new effective treatments, especially the use of biologic agents. Given its high prevalence, the variety of clinical manifestations, and the need for a multidisciplinary treatment approach, the study of arthropathic psoriasis remains a highly relevant field in modern rheumatology and dermatology.
References
Gossec, L., Baraliakos, X., Kerschbaumer, A., et al. (2020). EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases, 79(6), 700–712. https://doi.org/10.1136/annrheumdis-2020-217159
Singh, J. A., Guyatt, G., Ogdie, A., et al. (2019). 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis & Rheumatology, 71(1), 5–32. https://doi.org/10.1002/art.40726
Mease, P. J., Smolen, J. S., Behrens, F., et al. (2021). A head-to-head comparison of IL-17A and TNF inhibitors in psoriatic arthritis: efficacy and safety results from randomized clinical trials. The Lancet Rheumatology, 3(7), e407–e417. https://doi.org/10.1016/S2665-9913(21)00120-4
Coates, L. C., & Helliwell, P. S. (2020). Psoriatic arthritis: state of the art review. Clinical Medicine, 20(1), 70–74. https://doi.org/10.7861/clinmed.2019-0350
Ogdie, A., & Weiss, P. (2015). The epidemiology of psoriatic arthritis. Rheumatic Disease Clinics of North America, 41(4), 545–568. https://doi.org/10.1016/j.rdc.2015.07.001
Gladman, D. D., Antoni, C., Mease, P., et al. (2005). Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Annals of the Rheumatic Diseases, 64(Suppl 2), ii14–ii17. https://doi.org/10.1136/ard.2004.032482
Ritchlin, C. T., Colbert, R. A., & Gladman, D. D. (2017). Psoriatic Arthritis. New England Journal of Medicine, 376(10), 957–970. https://doi.org/10.1056/NEJMra1505557
McInnes, I. B., & Schett, G. (2017). Pathogenetic insights from the treatment of psoriatic arthritis. The Lancet, 389(10086), 1337–1346. https://doi.org/10.1016/S0140-6736(16)32461-6
Mease, P. J., Rahman, P., Gottlieb, A. B., et al. (2020). Efficacy of guselkumab, an IL-23 inhibitor, in psoriatic arthritis: results from a phase 3 trial. Arthritis & Rheumatology, 72(10), 1793–1803. https://doi.org/10.1002/art.41376
Kavanaugh, A., & Helliwell, P. (2022). JAK inhibitors in psoriatic arthritis: a new therapeutic option. Rheumatology (Oxford), 61(SI2), ii47–ii53. https://doi.org/10.1093/rheumatology/keac203
